bioMérieux S.A. (FRA:EYWN)

bioMérieux Statistics

Total Valuation

bioMérieux has a market cap or net worth of EUR 13.42 billion. The enterprise value is 13.55 billion.

Market Cap	13.42B
Enterprise Value	13.55B

Important Dates

The next estimated earnings date is Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	Jun 9, 2025

Share Statistics

Current Share Class	118.07M
Shares Outstanding	n/a
Shares Change (YoY)	+0.08%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	18.74%
Float	44.73M

Valuation Ratios

The trailing PE ratio is 35.52 and the forward PE ratio is 23.95.

PE Ratio	35.52
Forward PE	23.95
PS Ratio	3.26
PB Ratio	3.41
P/TBV Ratio	4.80
P/FCF Ratio	30.55
P/OCF Ratio	17.04
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.12, with an EV/FCF ratio of 30.85.

EV / Earnings	35.87
EV / Sales	3.29
EV / EBITDA	13.12
EV / EBIT	19.26
EV / FCF	30.85

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.13.

Current Ratio	2.27
Quick Ratio	1.30
Debt / Equity	0.13
Debt / EBITDA	0.49
Debt / FCF	1.15
Interest Coverage	45.70

Financial Efficiency

Return on equity (ROE) is 9.49% and return on invested capital (ROIC) is 9.90%.

Return on Equity (ROE)	9.49%
Return on Assets (ROA)	8.23%
Return on Invested Capital (ROIC)	9.90%
Return on Capital Employed (ROCE)	16.14%
Revenue Per Employee	285,226
Profits Per Employee	26,150
Employee Count	14,754
Asset Turnover	0.77
Inventory Turnover	1.81

Taxes

In the past 12 months, bioMérieux has paid 138.40 million in taxes.

Income Tax	138.40M
Effective Tax Rate	27.18%

Stock Price Statistics

The stock price has increased by +5.12% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+5.12%
50-Day Moving Average	116.30
200-Day Moving Average	116.80
Relative Strength Index (RSI)	40.00
Average Volume (20 Days)	67

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, bioMérieux had revenue of EUR 4.12 billion and earned 377.90 million in profits. Earnings per share was 3.17.

Revenue	4.12B
Gross Profit	2.32B
Operating Income	703.80M
Pretax Income	509.20M
Net Income	377.90M
EBITDA	999.50M
EBIT	703.80M
Earnings Per Share (EPS)	3.17

Balance Sheet

The company has 380.50 million in cash and 506.40 million in debt, giving a net cash position of -125.90 million.

Cash & Cash Equivalents	380.50M
Total Debt	506.40M
Net Cash	-125.90M
Net Cash Per Share	n/a
Equity (Book Value)	3.94B
Book Value Per Share	33.32
Working Capital	1.27B

Cash Flow

In the last 12 months, operating cash flow was 787.70 million and capital expenditures -348.30 million, giving a free cash flow of 439.40 million.

Operating Cash Flow	787.70M
Capital Expenditures	-348.30M
Free Cash Flow	439.40M
FCF Per Share	n/a

Margins

Gross margin is 56.27%, with operating and profit margins of 17.08% and 9.17%.

Gross Margin	56.27%
Operating Margin	17.08%
Pretax Margin	12.35%
Profit Margin	9.17%
EBITDA Margin	24.25%
EBIT Margin	17.08%
FCF Margin	10.66%

Dividends & Yields

This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 0.81%.

Dividend Per Share	0.90
Dividend Yield	0.81%
Dividend Growth (YoY)	5.88%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.08%
Shareholder Yield	0.73%
Earnings Yield	2.82%
FCF Yield	3.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.

Last Split Date	Sep 20, 2017
Split Type	Forward
Split Ratio	3

Scores

bioMérieux has an Altman Z-Score of 6.89 and a Piotroski F-Score of 7.

Altman Z-Score	6.89
Piotroski F-Score	7